Page 23 - Financial Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

German NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021 Organization streamlined with a focus on cost savings and progressing vamorolone Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point Further strengthening of Santhera’s capital structure through a proposed convertible bond restructuring supported by its largest convertible bondholder representing approx. 32% of total bonds outstanding

Switzerland generalUnited statesEva kaliasDario eklundLife science allianceSanthera pharmaceuticalsSwiss financial services act finHead external communicationsDrug administrationSanthera pharmaceuticals holdingStifel nicolaus europeEuropean medicines agencyChiesi groupHighbridge tactical credit master fundHighbridge capital managementExtraordinary general meeting